Dosing of Antihypertensive Medications in Patients with Renal Insufficiency
- 1 January 1995
- journal article
- review article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 35 (1) , 81-86
- https://doi.org/10.1002/j.1552-4604.1995.tb04749.x
Abstract
The use of antihypertensive agents in patients with renal insufficiency necessitates careful consideration of dosages, titration, and monitoring. Renal function must be estimated to appropriately make dosage adjustments for antihypertensives that exhibit extensive renal elimination. Thiazide diuretics are useful in mild degrees of renal insufficiency but loop diuretics become necessary as renal function deteriorates further. With either class, low dosages should be used to prevent hypovolemia, hyponatremia, and hypokalemia which may worsen renal blood flow. Angiotensin‐converting enzyme (ACE) inhibitors have become popular because they may have unique renal protective properties. All ACE inhibitors except fosinopril require reduced dosages and/or less frequent administration in patients with renal insufficiency. It is often necessary to use a diuretic with an ACE inhibitor and special dosing considerations are important. Due to demographic and physiologic characteristics of patients with renal insufficiency, beta blockers are often reserved for patients with other indications for beta blockers such as ischemic heart disease. Several beta blockers are eliminated primarily by the kidney and dosage reductions are necessary for these agents. Calcium antagonists may also have renal protective effects. Because calcium antagonists are metabolized extensively, significant dosage adjustments are not necessary. Data suggest that antihypertensives may slow the decline in renal insufficiency. The pharmacokinetics of several antihypertensives change with renal impairment because of reduced elimination. Therefore, dosage adjustments, slower titration, and less frequent administration are often necessary.Keywords
This publication has 47 references indexed in Scilit:
- Selected factors that influence responses to antihypertensives. Choosing therapy for the uncomplicated patientArchives of Family Medicine, 1994
- Clinical Pharmacokinetics of the Newer ACE InhibitorsClinical Pharmacokinetics, 1990
- Hemodynamic, Renal, and Humoral Effects of the Calcium Entry Blocker Nicardipine and Converting Enzyme Inhibitor Captopril in Hypertensive Type II Diabetic Patients with NephropathyJournal of Cardiovascular Pharmacology, 1989
- Renal effects of nicardipine, a calcium entry blocker, in hypertensive type II diabetic patients with nephropathyDiabetes, 1986
- Differential renal function during angiotensin converting enzyme inhibition in renovascular hypertension.Hypertension, 1986
- Redistribution of Cardiac Output to the Kidneys during Oral Nadolol AdministrationNew England Journal of Medicine, 1982
- Long‐Term Diuretic Therapy with Metolazone of Renal Failure and the Nephrotic SyndromeThe Journal of Clinical Pharmacology, 1977
- Metolazone, a diuretic agentAmerican Heart Journal, 1976
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976
- High Dosage Metolazone in Chronic Renal FailureBMJ, 1972